Sensorion to Present GJB2-GT Research at ESGCT Congress 2024
Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of innovative therapies for hearing loss, has announced its participation in the 31st Congress of the European Society of Gene and Cell Therapy (ESGCT), scheduled for October 22-25, 2024, in Rome, Italy.
At this prestigious event, Sensorion’s scientific team will present three significant posters highlighting advancements in their gene therapy drug candidate, GJB2-GT. This groundbreaking research program aims to restore hearing in patients affected by deafness linked to mutations in the GJB2 gene, which is the most common cause of hereditary deafness in children.
Key Presentations at the Congress:
- Professor Christine Petit, M.D., Ph.D. – A renowned expert and Professor Emeritus at Collège de France, will present a poster titled “GJB2 gene therapy-response of two pre-clinical mouse models of the most frequent form of human deafness, DFNB1.” This work, done in collaboration with Sensorion, delves into the efficacy of GJB2 gene therapy and its impact on different preclinical models. (Poster N°0273)
- Sandra Pierredon – A scientist from Sensorion’s Technology and Innovation Platform, will showcase her research on “Characterization of a safe and functional GT-GJB2 vector for the treatment of DFNB1A hearing loss.” This presentation will explore the safety and functionality of the gene therapy vector in preclinical models. (Poster N°0051)
- Laurent Désiré, Ph.D. – The Head of Preclinical Development at Sensorion, will present “Preclinical development of GT-GJB2 as a treatment for autosomal recessive non-syndromic deafness 1A (DFNB1A) using an adeno-associated vector-based gene therapy.” This poster will detail the development process and preclinical findings supporting the use of this gene therapy approach. (Poster N°0052)
These posters will be exhibited from October 22 to 23, 2024, and will be made available for further consultation on Sensorion’s website following the presentation sessions.
About Sensorion
Sensorion is committed to addressing the significant unmet medical need in the field of hearing loss disorders. By building a unique research and development technology platform, the company has enhanced its understanding of the pathophysiology and etiology of inner ear-related diseases, allowing it to identify the best targets and mechanisms of action for its drug candidates.
Sensorion has established two gene therapy programs specifically aimed at correcting hereditary monogenic forms of deafness. These programs are part of a broader strategic collaboration with the Institut Pasteur, focused on the genetics of hearing. The first program, SENS-501 (OTOF-GT), is currently in Phase 1/2 clinical trials and targets hearing loss caused by mutations in the otoferlin gene. The second, GJB2-GT, aims to address hearing loss associated with mutations in the GJB2 gene, with potential implications for both adults and children.
In addition to its gene therapy initiatives, Sensorion is also developing clinical-stage small molecule programs targeting various hearing loss disorders. Notably, its portfolio includes SENS-401 (Arazasetron), which is advancing in a planned Phase 2 proof-of-concept clinical study for cisplatin-induced ototoxicity and has been investigated in a study of patients undergoing cochlear implantation in collaboration with Cochlear Limited. Additionally, a Phase 2 study of SENS-401 for sudden sensorineural hearing loss (SSNHL) was completed in January 2022.
For more detailed information about Sensorion and its ongoing projects
